Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$3785.00
-110.00 (-2.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $7.0B · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$143.3B
P/E
262.7x
↑EV/EBITDA
4.3x
↓ROE
9.1%
↑Gross Margin
62.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.3%
FCF CAGR
+36.1%
FCF margin
27.0%
FCF / Net income
1.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $94.03B · net income $13.95B · FCF $25.39B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $94.03B | $94.03B | $72.04B | $72.98B | $76.03B |
| Net Income | $13.95B | $13.95B | $8.03B | $5.44B | $9.55B |
| EBITDA | $22.02B | $22.02B | $12.57B | $9.40B | $16.39B |
| EPS | 365.42 | 365.42 | 212.67 | 144.80 | 251.43 |
| Gross Margin | 62.2% | 62.2% | 53.5% | 54.2% | 54.7% |
| Operating Margin | 22.4% | 22.4% | 13.2% | 11.0% | 22.4% |
| Net Margin | 14.8% | 14.8% | 11.1% | 7.5% | 12.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Current Ratio | 4.52 | 4.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $25.39B | $25.39B | $410.0M | $7.05B | $10.08B |
| Returns | |||||
| ROE | 9.1% | 9.1% | 5.6% | 4.0% | 6.9% |
| Valuation | |||||
| P/E | 262.66 | 262.66 | 16.20 | 25.21 | 15.65 |
| EV/EBITDA | 4.28 | 4.28 | 6.62 | 8.66 | 5.63 |
| P/B | 0.95 | 0.95 | 0.90 | 1.01 | 1.08 |
| Growth & Yield | |||||
| Revenue Growth | 30.5% | 30.5% | -1.3% | -4.0% | — |
| EPS Growth | 71.8% | 71.8% | 46.9% | -42.4% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-2.8%
EPS terminal req.
$335.86
Spread vs growth
74.6%
5Y implied EPS CAGR
2.1%
EPS terminal req.
$406.39
Spread vs growth
69.7%
10Y implied EPS CAGR
6.0%
EPS terminal req.
$654.49
Spread vs growth
65.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.6%
Start / end P/E
17.5x → 10.4x
EPS bridge
212.67 → 365.42
Residual
-29.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.